Cargando…

Chitosan derivatives: A suggestive evaluation for novel inhibitor discovery against wild type and variants of SARS-CoV-2 virus

With increasing global cases and mortality rates due to COVID-19 infection, finding effective therapeutic interventions has become a top priority. Marine resources are not explored much and to be taken into consideration for exploring antiviral potential. Chitosan (carbohydrate polymer) is one such...

Descripción completa

Detalles Bibliográficos
Autores principales:	Modak, Chandrima, Jha, Anubhuti, Sharma, Nivya, Kumar, Awanish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313795/ https://www.ncbi.nlm.nih.gov/pubmed/34324908 http://dx.doi.org/10.1016/j.ijbiomac.2021.07.144

Ejemplares similares

Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: A plausible molecule against SARS-CoV-2?
por: Sharma, Nivya, et al.
Publicado: (2021)

Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants
por: Acharya, Arpan, et al.
Publicado: (2021)

Screening for inhibitors against SARS-CoV-2 and its variants
por: Yuan, Weijing, et al.
Publicado: (2022)

Identification of trans-2-cis-8-Matricaria-ester from the Essential Oil of Erigeron multiradiatus and Evaluation of Its Antileishmanial Potential by in Vitro and in Silico Approaches
por: Chandra Pandey, Satish, et al.
Publicado: (2019)

Suggesting Ritonavir against COVID-19/SARS-CoV-2
por: Choudhury, Shuvasish, et al.
Publicado: (2020)

Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases
por: Kühl, Nikos, et al.
Publicado: (2022)

Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2
por: Lee, Richard Kuan-Lin, et al.
Publicado: (2022)

PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron
por: Su, Jingyi, et al.
Publicado: (2022)

SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection
por: Bashor, Laura, et al.
Publicado: (2021)

SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection
por: Bashor, Laura, et al.
Publicado: (2021)

A chitosan-mediated inhalable nanovaccine against SARS-CoV-2
por: Zhuo, Shao-Hua, et al.
Publicado: (2022)

Rise and exacerbation of oral lichen planus in the background of SARS-CoV-2 infection
por: Sood, Anubhuti, et al.
Publicado: (2021)

Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
por: Amin, Sk Abdul, et al.
Publicado: (2021)

Plant-Derived Antiviral Compounds as Potential Entry Inhibitors against Spike Protein of SARS-CoV-2 Wild-Type and Delta Variant: An Integrative in SilicoApproach
por: Ambrose, Jenifer Mallavarpu, et al.
Publicado: (2022)

Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 Subunit
por: Kandeel, Mahmoud, et al.
Publicado: (2021)

Discovery of inhibitors against SARS-CoV-2 main protease using fragment-based drug design
por: Shao, Hai Ping, et al.
Publicado: (2023)

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2
por: Müller, Katharina, et al.
Publicado: (2021)

Evaluation of Potential Peptide-Based Inhibitors against SARS-CoV-2 and Variants of Concern
por: Boshah, Hattan, et al.
Publicado: (2023)

Discovery of M Protease Inhibitors Encoded by SARS-CoV-2
por: Hung, Hui-Chen, et al.
Publicado: (2020)

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors
por: Huff, Sarah, et al.
Publicado: (2021)

Nanobody derived using a peptide epitope from the spike protein receptor-binding motif inhibits entry of SARS-CoV-2 variants
por: Mendon, Nivya, et al.
Publicado: (2022)

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
por: Teli, Divya, et al.
Publicado: (2023)

A Comprehensive Technology Platform for the Rapid Discovery of Peptide Inhibitors against SARS-CoV-2 Pseudovirus Infection
por: Beeg, Marten, et al.
Publicado: (2023)

Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2
por: Shin, Young Sup, et al.
Publicado: (2021)

Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates
por: Wang, Yi, et al.
Publicado: (2021)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

Discovery of PL(pro) and M(pro) Inhibitors for SARS-CoV-2
por: Puhl, Ana C., et al.
Publicado: (2023)

A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus
por: Wang, Junzhi
Publicado: (2021)

Infection with Wild Type SARS-CoV-2 Combined with Vaccination Augments Neutralizing Antibody Levels Against Variants Including Omicron
por: O’Shea, Daniel, et al.
Publicado: (2023)

Battle against the pandemic: Emergence of SARS-CoV2 variants and global challenge
por: Kumar, Saurabh, et al.
Publicado: (2021)

Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery
por: Amin, Sk. Abdul, et al.
Publicado: (2021)

Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants
por: Ferdous, Nadim, et al.
Publicado: (2021)

Antibodies against SARS-CoV-2 Suggestive of Single Events of Spillover to Cattle, Germany
por: Wernike, Kerstin, et al.
Publicado: (2022)

Structure, dynamics and nanomechanics of wild-type and alpha-variant SARS-CoV-2 virions
por: Mudra, Dorottya, et al.
Publicado: (2022)

Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation
por: Guo, Sheng, et al.
Publicado: (2021)

Clinical Utility of Sero-Immunological Responses Against SARS-CoV-2 Nucleocapsid Protein During Subsequent Prevalence of Wild-Type, Delta Variant, and Omicron Variant
por: Lee, Beomki, et al.
Publicado: (2023)

Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants
por: Hollingsworth, Scott A., et al.
Publicado: (2023)

Identification of vaccine candidate against Omicron variant of SARS-CoV-2 using immunoinformatic approaches
por: Aasim, et al.
Publicado: (2022)

Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants
por: Wang, Rui, et al.
Publicado: (2021)

Genomic landscape of the SARS-CoV-2 pandemic in Brazil suggests an external P.1 variant origin
por: Perico, Camila P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hhdt9vb8amps7bdsjsaq6obf37